The Development of Next-Generation 5-HT Receptor Agonists as Neurotherapeutics
2:15 pm - Wednesday 16th September 2026
- How computational methods to molecular design accelerate the development of selective 5 HT–modulating neuroplastogens approaching first-in-human evaluation
- Leveraging behavioral readouts and advanced receptor profiling to refine mechanism-driven therapeutic hypotheses
- Integrating PD biomarkers to optimize next-generation non-hallucinogenic neuroplastogens
